CompletedPhase 2

Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia

France27 participantsStarted 2007-04

Plain-language summary

In patients with Core Binding Factors Acute Myelogenous Leukemia, the level of Minimal Residual Disease after chemotherapy is predictive of relapse. The relapse risk is also increased in case of mutations of receptors tyrosine kinase. For patients with a high Minimal Residual Disease level at the end of consolidation or in molecular relapse, maintenance by the inhibitor dasatinib is proposed.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient presenting de novo or secondary Core Binding Factors Acute Myelogenous Leukemia * Patient in first and presenting one of following criteria: * "Resistant" Patient: decrease of less than 3 log of the Acute Myelogenous Leukemia transcript level in the bone marrow after 2 consolidations * Patient in " molecular relapse ": increase of of more than 1 log of the Core Acute Myelogenous Leukemia transcript level on two successive marrow samples Exclusion Criteria: * Woman of childbearing potential * Concurrent incurable malignacy other than Acute Myelogenous Leukemia

What they're measuring

measure relapse-free survival

Timeframe: 4 years

Trial details

NCT IDNCT02113319

SponsorUniversity Hospital, Angers

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2012-05

View on ClinicalTrials.gov More Acute Myelogenous Leukemia trials